Boston-Cambridge biopharma ranked first in U.S.

The Boston-Cambridge biopharma cluster plays second fiddle to the San Francisco Bay area no more.

In a reversal of fortunes, Genetic Engineering and Biotechnology News, or GEN, this week ranked Massachusetts' cluster first in the nation, above last year's favorite — the Bay Area — followed by New York/New Jersey; San Diego; Maryland/Metro Washington, D.C.; Greater Philadelphia; Seattle; Raleigh-Durham, N.C.; Los Angeles; and Chicago and its suburbs.

"It's always nice to get accolades, but we can't really be satisfied until we're accelerating more cures and getting more remedies to bedsides," said Peter Abair, director of economic and global affairs at the trade group MassBio.

GEN said the Boston-Cambridge cluster ranked first on three measures: 2014 venture capital ($1.82 billion in 110 deals), National Institutes of Health funding ($312.797 million) and lab space (21.2 million square feet).

The cluster's 5,002 patents were second only to the Bay Area. And its lowest ranking — third — was on the number of industry jobs — 57,642 — behind New York/New Jersey and L.A., though it had the highest number per capita, said Susan Windham-Bannister, president and CEO of the Massachusetts Life Sciences Center, the quasi-public organization charged with administering the 10-year, $1 billion Life Sciences Initiative enacted by the Legislature in 2008.

What GEN also didn't include was the 17 Massachusetts biopharma IPOs last year, up from nine in 2013, and seven drug approvals, up from three the previous year, Abair said.

Anda sedang membaca artikel tentang

Boston-Cambridge biopharma ranked first in U.S.

Dengan url

http://terdiamtersipu.blogspot.com/2015/03/boston-cambridge-biopharma-ranked-first.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Boston-Cambridge biopharma ranked first in U.S.

namun jangan lupa untuk meletakkan link

Boston-Cambridge biopharma ranked first in U.S.

sebagai sumbernya